Liminatus Pharma Agrees to Sell 260,001 Shares in $650,002.50 Private Placement

• Liminatus Pharma agreed November 2, 2026, to sell 260,001 common shares at $2.50 each in a private placement.
• The unregistered sale to a non-U.S. investor will generate gross proceeds of $650,002.50.
• The placement is expected to close on or about November 20, 2026.
• Net proceeds will fund working capital and general corporate purposes.
• The company will file a registration statement for resale of the shares within 60 days of closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-122012), on November 03, 2026, and is solely responsible for the information contained therein.